Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 72)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Pentoxifylline |
Approved, Investigational |
Phase 3 |
|
6493-05-6 |
4740 |
Synonyms:
Agapurin
BL-191
BL-191|Trental®
C04AD03
EHT0201
NEOTREN MR
NSC-637086
Oxpentifylline
Pentoxifilina
|
Pentoxifyllin
Pentoxifylline
Pentoxifyllinum
Pentoxil
Torental
Trental
TRENTAL 100
TRENTAL 400
|
|
2 |
|
Mogamulizumab |
Approved, Investigational |
Phase 3 |
|
1159266-37-1 |
|
Synonyms:
AMG-761
KM8761
KM-8761
KW-0761
KW-0761|mogamulizumab-kpkc|Poteligeo®
|
MOGAMULIZUMAB
MOGAMULIZUMAB (GENETICAL RECOMBINATION)
MOGAMULIZUMAB-KPKC
POTELIGEO
|
|
3 |
|
Radiation-Protective Agents |
|
Phase 3 |
|
|
|
4 |
|
Phosphodiesterase Inhibitors |
|
Phase 3 |
|
|
|
5 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
6 |
|
Platelet Aggregation Inhibitors |
|
Phase 3 |
|
|
|
7 |
|
Antioxidants |
|
Phase 3 |
|
|
|
8 |
|
Protective Agents |
|
Phase 3 |
|
|
|
9 |
|
Etoposide |
Approved |
Phase 2 |
|
33419-42-0 |
36462 |
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
10 |
|
Lenalidomide |
Approved |
Phase 2 |
|
191732-72-6 |
216326 |
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CC-5013
CC-5013|CDC-501|Revlimid®
CDC 501
CDC-501
Celgene brand OF lenalidomide
IMID-1
|
IMiD3
IMiD3 CPD
Lenalidomida
LENALIDOMIDE
Revimid
Revlimid
SYP-1512
|
|
11 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
12 |
|
Vincristine |
Approved, Investigational |
Phase 2 |
|
2068-78-2, 57-22-7 |
5978 |
Synonyms:
(+)-Vincristine
22-OXOVINCALEUKOBLASTIN
22-oxo-Vincaleukoblastine
22-Oxovincaleukoblastine
22-oxovincaleukoblastine|kyocristine|leurocristine sulfate|NSC-67574|Oncovin®
37231
Cellcristin
Citomid
Farmistin
Indole alkaloid
KYOCRISTINE
LCR
Leucristine
Leurocristine
LEUROCRISTINE SULFATE
LILLY-37231
Marqibo
MARQIBO KIT
NSC-67574
Onco TCS
Oncovin
Oncovine
Onkocristin
PFS, Vincasar
|
Sulfate, vincristine
Tecnocris
VCR
VIN
Vincasar
Vincasar PFS
VINCREX
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
VINCRISTINE
Vincristine sulfate
VINCRISTINE SULFATE PFS
VINCRISTINUM
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
|
|
13 |
|
Prednisone |
Approved, Vet_approved |
Phase 2 |
|
53-03-2 |
5865 |
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
14 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
15 |
|
Zidovudine |
Approved |
Phase 2 |
|
30516-87-1 |
35370 |
Synonyms:
3' Azido 2',3' dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-dideoxythymidine
3'-Azido-3'-deoxythymidine
Antiviral azt
Apo-Zidovudine
Azidothymidine
AZT
AZT (antiviral)
AZT antiviral
AZT, antiviral
Aztec
BW a509U
BWA 509u
BWA509u
|
BWA-509u
BW-A509U
BW-A-509U
COMPOUND S
COMPOUND-S
Novo-Azt
NSC-602670
Retrovir
ZDV
Zidovudin
Zidovudina
Zidovudine
Zidovudine EP III
Zidovudinum
|
|
16 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
17 |
|
Lamivudine |
Approved, Investigational |
Phase 2 |
|
134678-17-4 |
60825 |
Synonyms:
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-2'-Deoxy-3'-thiacytidine
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3'-Thia-2',3'-dideoxycytidine
BCH 189
BCH 189, (-)-
BCH-189
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
Epivir
|
EPIVIR-HBV
Epzicom
GR-109714X
Hepitec
HEPTOVIR
LAMIVUDIN
LAMIVUDINA
LAMIVUDINE
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-isomer
LAMIVUDINUM
ZEFFIX
Β-L-2',3'-dideoxy-3'-thiacytidine
Β-L-3'-thia-2',3'-dideoxycytidine
|
|
18 |
|
Interferon beta-1a |
Approved, Investigational |
Phase 2 |
|
145258-61-3 |
|
Synonyms:
AVONEX
Belerofon
FIBROBLAST INTERFERON
IFN BETA 1A
IFN-BETA
Interferon beta 1a
Interferon beta 1-a
INTERFERON BETA PRECURSOR
|
Interferon beta-1a
Interferon beta-1a (recombinant human)
Interferon beta-1a,recombinant
Interferon-beta-1a
NEOFERON
REBIF
SNG001
|
|
19 |
|
Bortezomib |
Approved, Investigational |
Phase 1, Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
20 |
|
Rituximab |
Approved |
Phase 2 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
21 |
|
Teriflunomide |
Approved |
Phase 1, Phase 2 |
|
108605-62-5, 163451-81-8 |
54677977 54684141 |
Synonyms:
(Z)-2-CYANO-ALPHA,ALPHA,ALPHA-TRIFLUORO-3-HYDROXY-P-CROTONOTOLUIDIDE
A 771726
A 77-1726
A77 1726
A77 1726|Aubagio®|flucyamide|HMR-1726
A771726
AUBAGIO
FLUCYAMIDE
HMR 1726
|
HMR1726
HMR-1726
LEFLUNOMIDE RELATED COMPOUND B
LEFLUNOMIDE RELATED COMPOUND B RS
TERIFLUNOMIDA
TERIFLUNOMIDE
TÉRIFLUNOMIDE
TERIFLUNOMIDUM
|
|
22 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
23 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
24 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
25 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
26 |
|
Etoposide phosphate |
|
Phase 2 |
|
|
16760419 |
Synonyms:
{4-[16-({7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-D][1,3]dioxin-6-yl}oxy)-12-oxo-4,6,13-trioxatetracyclo[7.7.0.0,.0,]hexadeca-1,3(7),8-trien-10-yl]-2,6-dimethoxyphenoxy}phosphonate
BMY-40481
ETOPOPHOS
ETOPOPHOS PRESERVATIVE FREE
|
ETOPOSIDE PHOSPHATE
Etoposide phosphoric acid
VP16
VP-16
|
|
27 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
28 |
|
Hormones |
|
Phase 2 |
|
|
|
29 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
30 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
31 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
32 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
33 |
|
glucocorticoids |
|
Phase 2 |
|
|
|
34 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
35 |
|
Liposomal doxorubicin |
|
Phase 2 |
|
|
|
36 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
37 |
|
Reverse Transcriptase Inhibitors |
|
Phase 2 |
|
|
|
38 |
|
Interferon alpha-2 |
|
Phase 2 |
|
|
|
39 |
|
Lamivudine, zidovudine drug combination |
|
Phase 2 |
|
|
|
40 |
|
interferons |
|
Phase 2 |
|
|
|
41 |
|
Interferon-alpha |
|
Phase 2 |
|
|
|
42 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
43 |
|
Interferon-beta |
|
Phase 2 |
|
|
|
44 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
45 |
|
Anti-Inflammatory Agents |
|
Phase 1, Phase 2 |
|
|
|
46 |
|
Immunosuppressive Agents |
|
Phase 1, Phase 2 |
|
|
|
47 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
48 |
|
Analgesics |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Analgesics, Non-Narcotic |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show all 29)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) |
Unknown status |
NCT01343355 |
Phase 2, Phase 3 |
Tamibarotene |
2 |
Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. |
Completed |
NCT01472263 |
Phase 3 |
Pentoxifylline;Placebo |
3 |
A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) |
Terminated |
NCT03191526 |
Phase 3 |
KW-0761 0.3 mg/kg IV;Placebo (saline) |
4 |
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma |
Completed |
NCT02631746 |
Phase 2 |
|
5 |
Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma |
Completed |
NCT00041327 |
Phase 2 |
Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine |
6 |
Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a |
Completed |
NCT00001785 |
Phase 2 |
Recombinant human interferon beta-1a |
7 |
Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma |
Completed |
NCT01000285 |
Phase 1, Phase 2 |
Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir |
8 |
A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma |
Completed |
NCT01274533 |
Phase 2 |
Lenalidomide |
9 |
Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy |
Recruiting |
NCT04004819 |
Phase 2 |
Rituximab |
10 |
Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis |
Recruiting |
NCT04799288 |
Phase 1, Phase 2 |
Teriflunomide |
11 |
Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) |
Terminated |
NCT03075553 |
Phase 2 |
|
12 |
Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load |
Withdrawn |
NCT01620736 |
Phase 2 |
Raltegravir |
13 |
A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder |
Unknown status |
NCT01640002 |
Phase 1 |
Propantheline Bromide;Placebo |
14 |
Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy |
Unknown status |
NCT02961712 |
Phase 1 |
|
15 |
Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action |
Completed |
NCT00076843 |
Phase 1 |
Hu MiK-Beta-1 |
16 |
A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM) |
Recruiting |
NCT05240612 |
Phase 1 |
|
17 |
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) |
Recruiting |
NCT04301076 |
Phase 1 |
Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate |
18 |
Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 |
Completed |
NCT01651819 |
|
|
19 |
Epidemic History and Iatrogenic Transmission of Blood-borne Viruses |
Completed |
NCT02439918 |
|
|
20 |
Therapeutic Effect of the Pilates Method in People With HAM/TSP: a Randomized Crossover Study |
Completed |
NCT04830319 |
|
|
21 |
Sensorimotor Exercises in Virtual Reality Platform and Balance in Individuals With Human T-lymphotropic Virus |
Completed |
NCT02877030 |
|
|
22 |
Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study |
Completed |
NCT02655471 |
Early Phase 1 |
"Raltegravir" and "Zidovudine" |
23 |
Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) |
Completed |
NCT01867320 |
Early Phase 1 |
Raltegravir |
24 |
MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) |
Completed |
NCT00034723 |
|
|
25 |
Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 |
Completed |
NCT01754311 |
|
|
26 |
Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP) |
Recruiting |
NCT00001778 |
|
|
27 |
Physical Functional Impacts of Rehabilitation in Patients With Human Lymphotropic Virus Type I |
Recruiting |
NCT04875403 |
|
|
28 |
Caractérisation Clinico- Biologique et Survie Des Patients Porteurs d'Une lymphoprolifération HTLV-1 Induite (ou Lymphome/leucémie lié au Virus HTLV-1) et Des Patients infectés Par le Virus HTLV-1 |
Recruiting |
NCT05237245 |
|
|
29 |
Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection |
Recruiting |
NCT00001582 |
|
|
|